Hysbysiad gwybodaeth ymlaen llaw
Hysbysiad gwybodaeth ymlaen llaw yn unig yw hwn
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
NHS West Yorkshire ICB
Suites 2-4, Wira Business Park
Leeds
LS16 6EB
UK
Person cyswllt: Ben Pursey
E-bost: wyicb-kirk.procurement@nhs.net
NUTS: UKE4
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://www.westyorkshire.icb.nhs.uk/
I.3) Cyfathrebu
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
NHS WYICB - Optimising Diabetes Pathway Management Through Greater Data Utilisation (Data Platform & Architecture)
Cyfeirnod: WYICBODPMTGDU1
II.1.2) Prif god CPV
85000000
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
West Yorkshire Integrated Care Board (ICB) are running an early market engagement exercise to identify suppliers who may be interested in working in partnership to optimise management of the West Yorkshire diabetes pathway through the greater use of data.
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Na
II.2) Disgrifiad
II.2.2) Cod(au) CPV ychwanegol
72300000
II.2.3) Man cyflawni
Cod NUTS:
UKE4
II.2.4) Disgrifiad o’r caffaeliad
West Yorkshire Integrated Care Board (ICB) are running an early market engagement exercise to identify suppliers who may be interested in working in partnership to optimise management of the West Yorkshire diabetes pathway through the greater use of data.
A Technology Appraisal (TA943) published by the National Institute for Clinical Excellence (NICE) in December 2023 recommended the use of hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. In partnership with the NHS England Diabetes Programme, a 5 year implementation strategy has been agreed for rolling out this technology across all target patient groups and across all ICBs within England.
The roll-out of hybrid closed loop technologies brings with it increased flows of data within the system from the providers of such technologies, additional national clinical reporting requirements, and additional complexity in ensuring effective management of patients and the technologies they use. Currently, sharing, management, usage, and integration into national clinical data requirements is both challenging and disparate, relying on many systems (including clinical systems and those provided by technology suppliers) which don’t interface with one another. This challenge, and the scale of the data requirements, will only continue increasing as the 5 year implementation strategy progresses and the target population is widened.
West Yorkshire ICB are keen to be at the forefront of this challenge and have an appetite to develop a data architecture and platform capable of utilising these disparate data sets to provide an end-end, data and insight-led view of the diabetes pathway. By harnessing the benefits which hybrid closed loop technologies have the potential to offer through greater data utilisation and insights, it’s intended this approach will deliver both clinical and operational improvements and requirements. This includes meeting national operating requirements, improvements in the local implementation of pathways, and unlocking efficiencies, but importantly, the potential to deliver improved care for people with diabetes through pathway optimisation.
At this stage of the project, West Yorkshire ICB would like to engage with suppliers who would be interested in working in partnership to initially scope the current data provision, gaps, and insight needs, with a view to subsequently developing and implementing an appropriate data platform. Suppliers could include those interested in developing a bespoke platform, or those with their own existing data platform offering. For the avoidance of doubt, this notice is for early market engagement, and does not formally begin a procurement process or represent a commitment by West Yorkshire ICB to undertake an associated procurement process in the future.
More information
NICE Technology Appraisal TA943 Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes: https://www.nice.org.uk/guidance/ta943
NHS England Hybrid closed loop technologies 5-year implementation strategy: https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/
II.2.14) Gwybodaeth ychwanegol
If you would like to express an interest in this opportunity, please submit your response by registering on https://nhswyicb.ukp.app.jaggaer.com reference PQQ_59. Once registered, potential suppliers will be able to complete and upload their submission.
The closing date to express an interest is at 12:00 on Friday 26th July 2024.
NHS WYICB reserve the right to pull this process.
II.3) Dyddiad amcangyfrifedig ar gyfer cyhoeddi’r hysbysiad contract:
26/06/2024
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
Section VI: Gwybodaeth ategol
VI.3) Gwybodaeth ychwanegol
If you would like to express an interest in this opportunity, please submit your response by registering on https://nhswyicb.ukp.app.jaggaer.com reference PQQ_59.
Once registered, potential suppliers will be able to complete and upload their submission.
The closing date to express an interest is at 12:00 on Friday 26th July 2024.
In their response, suppliers should reference the following key points:
• Your approach to initial engagement with West Yorkshire ICB to scope the need, helping inform the art of the possible, and shaping future plans.
• Added benefits your organisation may bring e.g. connections into additional potential commercial partners.
• Funding your organisation may be able to access internally or externally to support the project through its future stages of development.
• Resource, capacity, and funding your organisation may be able to offer to the project prior to/outside of any contractual agreements or procurement exercises.
• Your organisational appetite to joint commercial ventures and approach to the development of foreground intellectual property.
VI.5) Dyddiad anfon yr hysbysiad hwn
28/06/2024